CA
CTKB icon

Clearstead Advisors’s Cytek Biosciences CTKB Stock Holding History

Clearstead Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209 Buy
+47
New +$201 ﹤0.01% 3191
2026
Q1 		– Sell
-24
Closed -$122 – 2388
2025
Q4 		$122 Sell
24
-1,051
-98% -$4.88K ﹤0.01% 2487
2025
Q3 		$3.73K Buy
1,075
+448
+71% +$1.68K ﹤0.01% 2267
2025
Q2 		$2.13K Buy
+627
New +$2.09K ﹤0.01% 2309

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Clearstead Advisors's CTKB Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 47 shares worth $209. The stake represents ﹤0.01% of the portfolio and ranks #3191 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in CTKB as recently as Q4 2025.

Clearstead Advisors first reported a position in CTKB in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.73K in Q3 2025. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Clearstead Advisors held 47 shares of Cytek Biosciences worth $209 as of Q2 2026.
  • Cytek Biosciences was a new Clearstead Advisors position in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3191 holding.
  • Clearstead Advisors first reported a position in Cytek Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Clearstead Advisors's Cytek Biosciences position peaked at $3.73K in Q3 2025.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.